

Sanjay Popat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8180337/sanjay-popat-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224 papers	9,817 citations	39 h-index	96 g-index
338 ext. papers	12,620 ext. citations	4.6 avg, IF	6.29 L-index

#	Paper	IF	Citations
224	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.. <i>Lung Cancer</i> , 2022 , 165, 34-42	5.9	2
223	Molecular Targetable Pathways ALK 2022 , 853-864		
222	Molecular Targetable Pathways EGFR 2022 , 844-852		
221	Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaEGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.. <i>European Journal of Cancer</i> , 2022 , 166, 38-40	7.5	0
220	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.. <i>Lung Cancer</i> , 2022 , 167, 8-16	5.9	1
219	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Mutations: An Updated Database of 1023 Cases Brief Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 834704	5.3	1
218	Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2022 , 18, 2499-2510	3.6	0
217	A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 915 PROMISE-meso phase III trial. <i>Lung Cancer</i> , 2022 , 169, 77-83	5.9	
216	Targeting un-MET needs in advanced non-small cell lung cancer.. <i>Lung Cancer</i> , 2021 , 164, 56-68	5.9	1
215	Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100253	1.4	
214	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naïve ALK + non-small cell lung cancer (ALTA-1L). <i>Lung Cancer</i> , 2021 , 155, 68-77	5.9	5
213	Y disruption, autosomal hypomethylation and poor male lung cancer survival. <i>Scientific Reports</i> , 2021 , 11, 12453	4.9	3
212	Biomarker Testing for People With Advanced Lung Cancer in England. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100176	1.4	2
211	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. <i>Drugs</i> , 2021 , 81, 971-984	4.1	2
210	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. <i>Lung Cancer</i> , 2021 , 156, 147-150	5.9	0
209	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021 , 10, LMT48	2.6	1
208	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 157, 9-16	5.9	2

207	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 764-773	8.9	47
206	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. <i>Oncologist</i> , 2021 , 26, e306-e315	5.7	9
205	Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. <i>Histopathology</i> , 2021 , 78, 434-444	7.3	2
204	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 375-386	4.0	209
203	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100114	1.4	3
202	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021 , 17, 4237-4247	3.6	3
201	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score 0 - Systematic review and meta-analysis. <i>Lung Cancer</i> , 2021 , 158, 97-106	5.9	9
200	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). <i>Lung Cancer</i> , 2021 , 162, 9-15	5.9	2
199	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2091-2108	8.9	19
198	Integrated genomics point to immune vulnerabilities in pleural mesothelioma. <i>Scientific Reports</i> , 2021 , 11, 19138	4.9	0
197	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021 , 125, 1210-1216	8.7	0
196	Pleural mesothelioma (PM) - The status of systemic therapy. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102265	4.4	1
195	Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.. <i>JCO Precision Oncology</i> , 2021 , 5, 39-43	3.6	1
194	1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2020 , 31, S826-S827	10.3	4
193	LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. <i>Annals of Oncology</i> , 2020 , 31, S1211	10.3	13
192	Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. <i>BMC Cancer</i> , 2020 , 20, 1210	4.8	2
191	Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of Translocation With Amplification. <i>JCO Oncology Practice</i> , 2020 , 16, 695-697	6.3	7
190	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. <i>Lung Cancer</i> , 2020 , 144, 76-84	5.9	14

189	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020 , 31, 107550	10.6	19
188	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 895-904	35.1	56
187	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 914-947	8.9	71
186	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020 , 127, 160-172	7.5	69
185	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 803-815	8.9	77
184	Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. <i>British Journal of Haematology</i> , 2020 , 189, e1-e3	4.5	1
183	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab 2020 , 8,		5
182	Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade. <i>Histopathology</i> , 2020 , 77, 423-436	7.3	5
181	Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9058-9058	2.2	12
180	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9517-9517	2.2	12
179	Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS1100-TPS1100	2.2	5
178	AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9633-TPS9633	2.2	10
177	Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. <i>Cancer Treatment and Research Communications</i> , 2020 , 25, 100261	2	0
176	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 139, 22-27	5.9	9
175	Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 347-356	6.7	15
174	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 416-425	8.9	13
173	A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. <i>Annals of Oncology</i> , 2020 , 31, 1734-1745	10.3	79
172	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020 , 583, 807-812	50.4	48

171	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. <i>Annals of Oncology</i> , 2020 , 31, S1441	10.3	4
170	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3592-3603 ¹⁰⁴	2.2	3
169	Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation. <i>Lung Cancer</i> , 2020 , 148, 12-19	5.9	13
168	Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e142-e144	8.9	3
167	Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. <i>BMJ Open</i> , 2020 , 10, e038892	3	14
166	EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e162-e165	8.9	8
165	Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, 842-844	2.3	4
164	Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. <i>Clinical Oncology</i> , 2020 , 32, 527-538	5.3	5
163	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. <i>Annals of Oncology</i> , 2019 , 30, 1321-1328	10.3	365
162	Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. <i>Lung Cancer</i> , 2019 , 134, 117-120	5.9	11
161	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. <i>Seminars in Oncology</i> , 2019 , 46, 145-154	5.5	9
160	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 569-580	35.1	82
159	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1655-1669	21.7	215
158	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9026-9026	2.2	3
157	Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9084-9084	2.2	6
156	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019 , 15, 1363-1383	3.6	8
155	P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines. <i>Journal of Thoracic Oncology</i> , 2019 , 14, S755-S756	8.9	4
154	A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. <i>PLoS ONE</i> , 2019 , 14, e0225509	3.7	

153	PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019 , 14, S7	8.9	3
152	P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases. <i>Journal of Thoracic Oncology</i> , 2019 , 14, S757	8.9	2
151	143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S84-S85	8.9	6
150	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. <i>Clinical Lung Cancer</i> , 2018 , 19, 42-50	4.9	5
149	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2018 , 19, 74-83.e11	4.9	23
148	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 63-72	8.9	18
147	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018 , 14, 2415-2431	3.6	19
146	213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S128	8.9	2
145	Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8515-8515	2.2	32
144	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9010-9010	2.2	33
143	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9072-9072	2.2	5
142	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)..	2.2	
141	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8566-8566	2.2	
140	149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S89-S90	8.9	2
139	MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S367	8.9	2
138	Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. <i>Annals of Oncology</i> , 2018 , 29, viii746	10.3	2
137	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S186	8.9	2
136	PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L). <i>Journal of Thoracic Oncology</i> , 2018 , 13, S184-S185	8.9	2

135	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. <i>Annals of Oncology</i> , 2018 , 29, viii497	10.3	10
134	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018 , 3, e000408	6	2
133	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv192-iv237	10.3	897
132	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2027-2039	59.2	427
131	Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. <i>European Journal of Cancer</i> , 2017 , 75, 56-62	7.5	4
130	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. <i>Future Oncology</i> , 2017 , 13, 1159-1171	3.6	12
129	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 435-444	35.1	133
128	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017 , 18, 589-593	4.9	11
127	Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 111, 51-58	5.9	11
126	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017 , 77, 813-827	12.1	32
125	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 201-216	5.4	22
124	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 595-604	4.9	34
123	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <i>PLoS ONE</i> , 2017 , 12, e0186106	3.7	12
122	Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. <i>Annals of Oncology</i> , 2017 , 28, ix74	10.3	2
121	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3591-3600	2.2	93
120	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1403-1410	2.2	198
119	Endocrine manifestations of malignancy. <i>Medicine</i> , 2017 , 45, 547-550	0.6	
118	Novel insights into mesothelioma biology and implications for therapy. <i>Nature Reviews Cancer</i> , 2017 , 17, 475-488	31.3	199

117	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. <i>Lung Cancer</i> , 2017 , 111, 6-11	5.9	2
116	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. <i>European Journal of Cancer</i> , 2017 , 87, 75-83	7.5	13
115	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1552-1560	8.9	55
114	Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. <i>Lung Cancer</i> , 2017 , 111, 65-68	5.9	13
113	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017 , 70, 12-21	7.5	28
112	P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S2397	8.9	3
111	MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1884	8.9	3
110	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8506-8506	2.2	1
109	Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8581-TPS8581	2.2	12
108	Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9098-TPS9098	2.2	1
107	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. <i>Oncology</i> , 2016 , 90, 280-8	3.6	7
106	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1627-43	8.9	46
105	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1029-39	8.9	31
104	Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer. <i>Lung Cancer</i> , 2016 , 92, 1-7	5.9	10
103	Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. <i>Future Oncology</i> , 2016 , 12, 815-25	3.6	3
102	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 380-90	8.9	240
101	A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 375-83	3.5	10
100	Sunitinib (SU11248) in patients with chemo naïve extensive small cell lung cancer or who have a chemosensitive relapse: A single-arm phase II study (EORTC-08061). <i>European Journal of Cancer</i> , 2016 , 54, 35-39	7.5	12

99	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts) 2016 ,		2
98	Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23027-e23027	2.2	1
97	Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8574-TPS8574	2.2	2
96	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 154-154	2.2	12
95	Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14048-e14048	2.2	
94	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20507-e20507	2.2	1
93	Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20107-e20107	2.2	
92	TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy	2.2	
91	Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. <i>Annals of Oncology</i> , 2016 , 27, vi22	10.3	2
90	ALTA-1L (ALK in lung cancer trial of Brigatinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI) naïve, advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016 , 27, vi448	10.3	2
89	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016 , 6, 838-851	24.4	176
88	Management of lung cancer. <i>Medicine</i> , 2016 , 44, 244-248	0.6	1
87	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <i>European Journal of Cancer</i> , 2016 , 60, 26-39	7.5	25
86	A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. <i>European Journal of Cancer</i> , 2016 , 61, 102-10	7.5	26
85	P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S216	8.9	5
84	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , 2015 , 16, 141-51	21.7	1081
83	Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership. <i>Lung Cancer</i> , 2015 , 89, 175-80	5.9	23
82	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). <i>European Journal of Cancer</i> , 2015 , 51, 1511-28	7.5	23

81	Never smoker with ground glass opacities on CT. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 328	35.1	
80	Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. <i>BMC Cancer</i> , 2015 , 15, 163	4.8	21
79	The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015 , 9, 97-104	4.9	3
78	3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. <i>European Journal of Cancer</i> , 2015 , 51, S711-S712	7.5	22
77	Response evaluation in mesothelioma: Beyond RECIST. <i>Lung Cancer</i> , 2015 , 90, 433-41	5.9	20
76	Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2015 , 11, 2525-40	3.6	17
75	Systemic therapy for pulmonary carcinoids. <i>Lung Cancer</i> , 2015 , 90, 139-47	5.9	14
74	Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment. <i>Cancer Treatment Communications</i> , 2015 , 4, 86-88		1
73	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. <i>BMC Research Notes</i> , 2015 , 8, 688	2.3	3
72	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. <i>PLoS ONE</i> , 2015 , 10, e0139074	3.7	41
71	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2015 , 11, 2175-91	3.6	4
70	76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI). <i>Lung Cancer</i> , 2015 , 87, S30	5.9	3
69	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2015 , 11, 409-20	3.6	28
68	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2508-2508	2.2	28
67	TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8109-TPS8109	2.2	1
66	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 1254-62	21.7	71
65	Understanding lung cancer molecular subtypes. <i>Clinical Practice (London, England)</i> , 2014 , 11, 441-453	3	1
64	Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. <i>Lung Cancer</i> , 2014 , 85, 230-8	5.9	40

63	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 285-95	2.1	24
62	A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. <i>BMC Cancer</i> , 2014 , 14, 674	4.8	19
61	A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 769-74	8.9	37
60	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. <i>European Journal of Cancer</i> , 2014 , 50, 1717-1721	7.5	10
59	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS7612-TPS7612	2.2	1
58	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. <i>Journal of Thoracic Disease</i> , 2014 , 6, 356-68	2.6	1
57	A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7563-7563	2.2	
56	Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. <i>Annals of Palliative Medicine</i> , 2014 , 3, 19-21	1.7	5
55	Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. <i>BMC Cancer</i> , 2013 , 13, 207	4.8	9
54	Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. <i>Lung Cancer</i> , 2013 , 80, 1-4	5.9	62
53	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013 , 49, 2815-22	7.5	38
52	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013 , 119, 2383-90	6.4	36
51	The role of afatinib in the management of non-small cell lung carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1529-39	5.5	3
50	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2013 , 14, 1765-77	2.6	31
49	Endocrine manifestations of malignancy. <i>Medicine</i> , 2013 , 41, 570-572	0.6	
48	A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. <i>Lung Cancer</i> , 2013 , 80, 339-40	5.9	16
47	A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy. <i>Journal of Telemedicine and Telecare</i> , 2013 , 19, 148-152	6.8	7
46	Treatment of Cancer 2013 , 27-44		

45	Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 783-7	8.9	64
44	FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS2626-TPS2626	2.2	4
43	Platelet counts (PLT) at baseline and on treatment as predictor for progression free survival (PFS) in patients with advanced malignant pleural mesothelioma (MPM): EORTC 08052 study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7585-7585	2.2	
42	Management of lung cancer. <i>Medicine</i> , 2012 , 40, 202-207	0.6	
41	Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. <i>European Journal of Cancer</i> , 2012 , 48, 61-7	7.5	27
40	ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. <i>Lung Cancer</i> , 2012 , 75, 300-5	5.9	38
39	True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 75, 133-5	5.9	4
38	Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. <i>Medical Oncology</i> , 2012 , 29, 2623-5	3.7	5
37	Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1962-3	8.9	62
36	Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. <i>PLoS ONE</i> , 2011 , 6, e25164	3.7	68
35	Guidelines on the radical management of patients with lung cancer. <i>Thorax</i> , 2010 , 65 Suppl 3, iii1-27	7.3	274
34	The combination of Young's syndrome and small cell lung cancer-A spiky connection?. <i>Lung Cancer</i> , 2010 , 67, 372-5	5.9	
33	Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , 2010 , 11, E5-8	4.9	3
32	Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1397-403	8.9	20
31	Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 436-41	8.9	172
30	Endocrine manifestations of malignancy. <i>Medicine</i> , 2009 , 37, 457-460	0.6	
29	Time trends in the outcome of elderly patients with breast cancer. <i>Breast Journal</i> , 2008 , 14, 158-63	1.2	8
28	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. <i>Lung Cancer</i> , 2008 , 59, 227-31	5.9	12

27	Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 324-35		31
26	Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reports. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 539-41	8.9	
25	Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. <i>Cancer</i> , 2008 , 113, 3364-71	6.4	115
24	Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. <i>Lung Cancer</i> , 2007 , 56, 135-7	5.9	40
23	Malignant pleural mesothelioma: two cases in first degree relatives. <i>Lung Cancer</i> , 2007 , 57, 407-9	5.9	1
22	Gut microflora associated characteristics in first-degree relatives of children with celiac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 1204-8	2.4	21
21	Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 735-40	8.9	19
20	Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. <i>Anticancer Research</i> , 2007 , 27, 627-33	2.3	28
19	Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. <i>BMC Cancer</i> , 2006 , 6, 150	4.8	19
18	Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. <i>Clinical Cancer Research</i> , 2006 , 12, 6585-9	12.9	33
17	Palliative treatments for patients with inoperable gastroesophageal cancers. <i>International Journal of Palliative Nursing</i> , 2006 , 12, 306-17	0.9	3
16	Nonmedullary Thyroid Cancer and the Role of the Geneticist 2006 , 281-299		1
15	Systematic review of microsatellite instability and colorectal cancer prognosis. <i>Journal of Clinical Oncology</i> , 2005 , 23, 609-18	2.2	1328
14	A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. <i>European Journal of Cancer</i> , 2005 , 41, 2060-70	7.5	143
13	Chemotherapy strategies in the treatment of small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 361-72	2.4	13
12	Re: Reporting recommendations for tumor marker prognostic studies (REMARK). <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1855; author reply 1855-6	9.7	8
11	Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 858; author reply 858-9	9.7	1
10	Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers. <i>International Journal of Surgical Pathology</i> , 2005 , 13, 127-33	1.2	8

9	Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. <i>Carcinogenesis</i> , 2004 , 25, 369-73	4.6	28
8	Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 529-36	2.2	378
7	Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?. <i>Lung Cancer</i> , 2004 , 43, 369-70	5.9	6
6	Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 145, 70-3		8
5	Polymorphic sequence variants in medicine: a challenge and an opportunity. <i>Clinical Medicine</i> , 2003 , 3, 260-4	1.9	7
4	Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. <i>Annals of Human Genetics</i> , 2002 , 66, 125-37	2.2	5
3	Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 1477-9	2.2	2
2	Prevalence of the APC E1317Q variant in colorectal cancer patients. <i>Cancer Letters</i> , 2000 , 149, 203-6	9.9	40
1	Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. <i>Leukemia</i> , 1999 , 13, 1497-500	10.7	31